Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an exploratory study on the metabolic endotoxemia associated with type 2 diabetes. The investigators will measure systemic endotoxin level and lipid level after ingestion of high fat diet to evaluate the effect of gemigliptin, a DPP-4 inhibitor, on metabolic endotoxemia and lipemia induced by high fat diet.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: LG Life Sciences

Criteria

Inclusion Criteria:

• Age from 20 to 75

• At least 6 months from the diagnosis of type 2 diabetes

• Current diabetes treatment: life style modification and/or metformin and/or sulfornylurea

• No change of the diabetes treatment (drug number and dossage) in recent 3 months

• HbA1c 6.5% to 10%

Exclusion Criteria:

• Recent cardiovascular event in 6 months

• Concurrent use of statin or fibrate or ezetimibe

• Renal failure, chronic liver disease

• Pregnancy or lactation

• Use of other DPP-4 inhibitor or GLP-1 analogue in recent 3 months